glioblastoma malignant brain tumor brain tumor
Conditions
Interventions
thromboSeq, a blood test based on platelet RNA with in this study the goal of progression monitoring in glioblastoma.
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Radiologic suspicion of high grade glioma on MRI Eligible for resection Older than 18 years of age
Exclusion criteria
Exclusion criteria: Known malignancy elsewhere in the body
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in platelet RNA profile between blood taken at true progression and blood taken at pseudoprogression/radionecrosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Established clinical prognostic factors and TEP-Glioblastoma-score will be analyzed in univariate and multivariate models of progression free and overall survival. Also, the effect of temozolomide and radiotherapy on the platelet RNA profiles will be evaluated by comparing groups of samples collected at moment of these therapies, and at moments when these therapies are not provided. In addition, the tumor size will be correlated to the TEP-Glioblastoma-score, and the levels of individual platelet RNAs. Finally, gene ontology analyses will be performed, aiming to elucidate involved molecular pathways in the platelets as a response to the intracranial tumor status, including DAVID GO, and PANTHER GO, as described and performed by us previously. | — |
Countries
Netherlands
Contacts
Public ContactD Noske
Amsterdam UMC
Outcome results
None listed